Result of AGM

RNS Number : 7742A

hVIVO plc

31 May 2019

 

HVIVO PLC

("hVIVO" or the "Company")

Result of Annual General Meeting

London, UK, 31 May 2019: hVIVO plc (AIM: HVO), an industry leading clinical development services business pioneering human disease models based upon viral and allergen challenge, announces that, all resolutions proposed at its Annual General Meeting, held at 10.00am on 30 May 2019, were duly passed.

For further information please contact:

hVIVO plc
Trevor Phillips (Executive Chairman)	[phone]
Fleur Wood (EVP, Investor Relations & Communications)
Numis Securities Limited	[phone]
Freddie Barnfield (Nominated Adviser)
James Black / Michael Burke (Corporate Broking)
FTI Consulting
Simon Conway / Victoria Foster Mitchell	[phone]

Notes to Editors:

hVIVO plc ("hVIVO") is pioneering a human-based clinical trial platform to accelerate drug and vaccine development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV, HRV and respiratory indications, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 50 clinical studies and inoculated over 2500 volunteers.

 

END

 

 

RAGCKDDBKBKDFPN